Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,033.69 +15.30 (+0.30%) Dow
38,046.58 +143.29 (+0.38%) Nasdaq
15,681.23 +75.75 (+0.49%) Bitcoin USD
58,493.36 +1,151.21 (+2.01%) CMC Crypto 200
1,264.17 -6.57 (-0.52%)
LLY Sep 2024 370.000 put
| Previous close | 0.5700 |
| Open | 0.5700 |
| Bid | 0.1300 |
| Ask | 0.7700 |
| Strike | 370.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.5700 - 0.5700 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
Simply Wall St.Eli Lilly and Company (NYSE:LLY) Just Released Its First-Quarter Earnings: Here's What Analysts Think
It's been a good week for Eli Lilly and Company ( NYSE:LLY ) shareholders, because the company has just released its...
Barrons.comNovo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock’s Falling.
The Danish pharmaceutical giant, which became Europe’s most valuable company last year, said Wegovy sales jumped 106% in the first quarter.
- Reuters
UPDATE 6-Blockbuster obesity drug demand drives Novo Nordisk profit boost
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Jyske Bank said the beat and upgrade were driven by a one-off U.S. sales adjustment, while underlying growth was a bit weaker than expected. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before Thursday's earnings, on the back of Wegovy's popularity.
